Chloride intracellular channel 1 activity is not required for glioblastoma development but its inhibition dictates glioma stem cell responsivity to novel biguanide derivatives.
Biguanide derivatives
CLIC1
GBM organoids
Glioblastoma stem cells
Targeted therapy
Journal
Journal of experimental & clinical cancer research : CR
ISSN: 1756-9966
Titre abrégé: J Exp Clin Cancer Res
Pays: England
ID NLM: 8308647
Informations de publication
Date de publication:
08 Feb 2022
08 Feb 2022
Historique:
received:
03
08
2021
accepted:
07
12
2021
entrez:
9
2
2022
pubmed:
10
2
2022
medline:
29
3
2022
Statut:
epublish
Résumé
Chloride intracellular channel-1 (CLIC1) activity controls glioblastoma proliferation. Metformin exerts antitumor effects in glioblastoma stem cells (GSCs) inhibiting CLIC1 activity, but its low potency hampers its translation in clinical settings. We synthesized a small library of novel biguanide-based compounds that were tested as antiproliferative agents for GSCs derived from human glioblastomas, in vitro using 2D and 3D cultures and in vivo in the zebrafish model. Compounds were compared to metformin for both potency and efficacy in the inhibition of GSC proliferation in vitro (MTT, Trypan blue exclusion assays, and EdU labeling) and in vivo (zebrafish model), migration (Boyden chamber assay), invasiveness (Matrigel invasion assay), self-renewal (spherogenesis assay), and CLIC1 activity (electrophysiology recordings), as well as for the absence of off-target toxicity (effects on normal stem cells and toxicity for zebrafish and chick embryos). We identified Q48 and Q54 as two novel CLIC1 blockers, characterized by higher antiproliferative potency than metformin in vitro, in both GSC 2D cultures and 3D spheroids. Q48 and Q54 also impaired GSC self-renewal, migration and invasion, and displayed low systemic in vivo toxicity. Q54 reduced in vivo proliferation of GSCs xenotransplanted in zebrafish hindbrain. Target specificity was confirmed by recombinant CLIC1 binding experiments using microscale thermophoresis approach. Finally, we characterized GSCs from GBMs spontaneously expressing low CLIC1 protein, demonstrating their ability to grow in vivo and to retain stem-like phenotype and functional features in vitro. In these GSCs, Q48 and Q54 displayed reduced potency and efficacy as antiproliferative agents as compared to high CLIC1-expressing tumors. However, in 3D cultures, metformin and Q48 (but not Q54) inhibited proliferation, which was dependent on the inhibition dihydrofolate reductase activity. These data highlight that, while CLIC1 is dispensable for the development of a subset of glioblastomas, it acts as a booster of proliferation in the majority of these tumors and its functional expression is required for biguanide antitumor class-effects. In particular, the biguanide-based derivatives Q48 and Q54, represent the leads to develop novel compounds endowed with better pharmacological profiles than metformin, to act as CLIC1-blockers for the treatment of CLIC1-expressing glioblastomas, in a precision medicine approach.
Sections du résumé
BACKGROUND
BACKGROUND
Chloride intracellular channel-1 (CLIC1) activity controls glioblastoma proliferation. Metformin exerts antitumor effects in glioblastoma stem cells (GSCs) inhibiting CLIC1 activity, but its low potency hampers its translation in clinical settings.
METHODS
METHODS
We synthesized a small library of novel biguanide-based compounds that were tested as antiproliferative agents for GSCs derived from human glioblastomas, in vitro using 2D and 3D cultures and in vivo in the zebrafish model. Compounds were compared to metformin for both potency and efficacy in the inhibition of GSC proliferation in vitro (MTT, Trypan blue exclusion assays, and EdU labeling) and in vivo (zebrafish model), migration (Boyden chamber assay), invasiveness (Matrigel invasion assay), self-renewal (spherogenesis assay), and CLIC1 activity (electrophysiology recordings), as well as for the absence of off-target toxicity (effects on normal stem cells and toxicity for zebrafish and chick embryos).
RESULTS
RESULTS
We identified Q48 and Q54 as two novel CLIC1 blockers, characterized by higher antiproliferative potency than metformin in vitro, in both GSC 2D cultures and 3D spheroids. Q48 and Q54 also impaired GSC self-renewal, migration and invasion, and displayed low systemic in vivo toxicity. Q54 reduced in vivo proliferation of GSCs xenotransplanted in zebrafish hindbrain. Target specificity was confirmed by recombinant CLIC1 binding experiments using microscale thermophoresis approach. Finally, we characterized GSCs from GBMs spontaneously expressing low CLIC1 protein, demonstrating their ability to grow in vivo and to retain stem-like phenotype and functional features in vitro. In these GSCs, Q48 and Q54 displayed reduced potency and efficacy as antiproliferative agents as compared to high CLIC1-expressing tumors. However, in 3D cultures, metformin and Q48 (but not Q54) inhibited proliferation, which was dependent on the inhibition dihydrofolate reductase activity.
CONCLUSIONS
CONCLUSIONS
These data highlight that, while CLIC1 is dispensable for the development of a subset of glioblastomas, it acts as a booster of proliferation in the majority of these tumors and its functional expression is required for biguanide antitumor class-effects. In particular, the biguanide-based derivatives Q48 and Q54, represent the leads to develop novel compounds endowed with better pharmacological profiles than metformin, to act as CLIC1-blockers for the treatment of CLIC1-expressing glioblastomas, in a precision medicine approach.
Identifiants
pubmed: 35135603
doi: 10.1186/s13046-021-02213-0
pii: 10.1186/s13046-021-02213-0
pmc: PMC8822754
doi:
Substances chimiques
Biguanides
0
CLIC1 protein, human
0
Chloride Channels
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
53Informations de copyright
© 2022. The Author(s).
Références
Mol Neurobiol. 2017 Sep;54(7):4879-4895
pubmed: 27514754
Front Genet. 2019 Nov 15;10:1143
pubmed: 31803233
Med Oncol. 2015 Jun;32(6):616
pubmed: 25920608
J Biol Chem. 2009 Mar 13;284(11):7138-48
pubmed: 19147502
Lancet Oncol. 2009 May;10(5):459-66
pubmed: 19269895
Cell Rep. 2019 Mar 19;26(12):3203-3211.e5
pubmed: 30893594
Nat Commun. 2020 Sep 16;11(1):4660
pubmed: 32938908
Cancer Cell. 2019 May 13;35(5):798-815.e5
pubmed: 31031016
Strahlenther Onkol. 2015 Dec;191(12):928-35
pubmed: 26329695
Molecules. 2020 Jan 23;25(3):
pubmed: 31979318
Front Cell Neurosci. 2017 Oct 13;11:312
pubmed: 29081734
Front Pharmacol. 2018 Aug 21;9:899
pubmed: 30186163
Biochemistry. 2017 Sep 12;56(36):4786-4798
pubmed: 28766937
Cancer Res. 2016 Apr 15;76(8):2465-77
pubmed: 26896279
Drug Discov Today. 2016 Jan;21(1):190-199
pubmed: 26456577
Cancer Cell. 2006 May;9(5):391-403
pubmed: 16697959
Profiles Drug Subst Excip Relat Methodol. 2021;46:273-307
pubmed: 33461699
Biochem J. 2014 Sep 15;462(3):475-87
pubmed: 25017630
Cancers (Basel). 2020 Jan 15;12(1):
pubmed: 31952173
Mol Cell Biochem. 2012 Jun;365(1-2):313-21
pubmed: 22426742
Bioorg Chem. 2020 Dec;105:104337
pubmed: 33113408
Clin Pharmacokinet. 2011 Feb;50(2):81-98
pubmed: 21241070
Oncotarget. 2014 Nov 30;5(22):11252-68
pubmed: 25361004
Cell Cycle. 2013 Feb 1;12(3):491-500
pubmed: 23324350
Sci Rep. 2018 Mar 2;8(1):3929
pubmed: 29500390
Stem Cells Transl Med. 2012 Nov;1(11):811-24
pubmed: 23197693
Exp Ther Med. 2018 Jun;15(6):4943-4949
pubmed: 29805518
World J Gastroenterol. 2014 Feb 28;20(8):2071-8
pubmed: 24587680
Front Cell Neurosci. 2020 Oct 16;14:558381
pubmed: 33177991
Eur J Med Chem. 2017 Jul 28;135:467-478
pubmed: 28477572
Mol Cancer Ther. 2018 Nov;17(11):2451-2461
pubmed: 30135216
J Chem Soc. 1946 Nov;:1063-9
pubmed: 20282483
Int J Cancer. 2020 Feb 1;146(3):803-809
pubmed: 30980539
NPJ Precis Oncol. 2021 Apr 12;5(1):30
pubmed: 33846504
Cancer Res. 2011 Jul 1;71(13):4366-72
pubmed: 21540236
Cytotherapy. 2006;8(4):315-7
pubmed: 16923606
Neuro Oncol. 2018 Oct 1;20(suppl_4):iv1-iv86
pubmed: 30445539
BMC Bioinformatics. 2011 Aug 04;12:323
pubmed: 21816040
JAMA. 2014 Dec 24-31;312(24):2668-75
pubmed: 25536258
Glia. 2007 Nov 1;55(14):1469-85
pubmed: 17705195
Oncol Lett. 2017 Dec;14(6):7557-7564
pubmed: 29344202
Toxicology. 2013 Dec 15;314(2-3):209-20
pubmed: 24157575
Bioorg Chem. 2019 Jun;87:457-464
pubmed: 30927586
J Natl Cancer Inst. 2013 Nov 6;105(21):1644-55
pubmed: 24115360
Eur J Med Chem. 2021 Nov 15;224:113726
pubmed: 34364161
Neuro Oncol. 2019 Jan 1;21(1):59-70
pubmed: 30053126
Elife. 2014 May 13;3:e02242
pubmed: 24843020
Curr Protoc Bioinformatics. 2015 Sep 03;51:11.14.1-11.14.19
pubmed: 26334920
Biomed Res Int. 2014;2014:126586
pubmed: 24527434
Diabetes Care. 2012 Jun;35(6):1364-79
pubmed: 22517736
Cancer. 2019 Feb 1;125(3):424-433
pubmed: 30359477
Cancer Sci. 2017 Jun;108(6):1240-1252
pubmed: 28378944
Drug Discov Today. 2008 May;13(9-10):394-401
pubmed: 18468556
Front Neurosci. 2020 Nov 25;14:603647
pubmed: 33324155
Endocrine. 2017 Aug;57(2):214-219
pubmed: 27481363
Sci Rep. 2018 Oct 3;8(1):14725
pubmed: 30282979
Stem Cell Res Ther. 2017 May 25;8(1):119
pubmed: 28545562
Trends Pharmacol Sci. 2013 Feb;34(2):126-35
pubmed: 23277337
Front Endocrinol (Lausanne). 2018 Aug 21;9:372
pubmed: 30186229
Eur J Med Chem. 2017 Feb 15;127:781-792
pubmed: 27823885
Methods. 2013 Mar;59(3):301-15
pubmed: 23270813
PLoS One. 2020 Jun 11;15(6):e0234571
pubmed: 32525922
Front Oncol. 2019 Mar 13;9:135
pubmed: 30918838
Cancers (Basel). 2020 Oct 21;12(10):
pubmed: 33096667
J Pers Med. 2021 Jul 05;11(7):
pubmed: 34357102
Neuro Oncol. 2019 Jan 1;21(1):4-5
pubmed: 30445513
PLoS One. 2013 Jul 10;8(7):e68808
pubmed: 23874773
FASEB J. 2000 Jun;14(9):1171-8
pubmed: 10834939
Cell Cycle. 2013 Jan 1;12(1):145-56
pubmed: 23255107
Oncogene. 2016 Nov 10;35(45):5819-5825
pubmed: 27041580
Drug Discov Today. 2012 Oct;17(19-20):1103-10
pubmed: 22704957
Biochim Biophys Acta. 2015 Oct;1848(10 Pt B):2523-31
pubmed: 25546839
Biochemistry. 2011 Dec 20;50(50):10887-97
pubmed: 22082111
Oncotarget. 2016 Jun 21;7(25):38638-38657
pubmed: 27229535
J Toxicol Pathol. 2020 Oct;33(4):197-210
pubmed: 33239838
J Exp Clin Cancer Res. 2012 May 11;31:44
pubmed: 22578365